Comparative Pharmacology
Head-to-head clinical analysis: AMINOCAPROIC ACID versus CYKLX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOCAPROIC ACID versus CYKLX.
AMINOCAPROIC ACID vs CYKLX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Competitive inhibition of plasminogen activation, reducing fibrinolysis by binding to plasminogen and blocking its conversion to plasmin.
CYKLX is a selective phosphodiesterase 4 (PDE4) inhibitor, increasing intracellular cyclic adenosine monophosphate (cAMP) levels and reducing pro-inflammatory cytokine production.
Loading dose: 4-5 g intravenously (IV) over 1 hour, followed by continuous IV infusion of 1 g/hour for 8 hours or until bleeding controlled. Oral: 1 g every hour for 8 hours, then 1 g every 2 hours for 8 additional hours.
100 mg orally once daily with food.
None Documented
None Documented
Terminal elimination half-life is approximately 2 hours (range 1-3 hours) in patients with normal renal function. Prolonged in renal impairment (up to 20 hours in anuria).
Clinical Note
moderateAminocaproic acid + Tretinoin
"Aminocaproic acid may increase the thrombogenic activities of Tretinoin."
Terminal half-life: 12 hours; requires dose adjustment in renal impairment (CrCl <30 mL/min).
Primarily renal (80-90% unchanged). A small fraction (<5%) is excreted as metabolites. No significant biliary/fecal elimination.
Renal: 70% unchanged; biliary/fecal: 30% as metabolites.
Category C
Category C
Antifibrinolytic
Antifibrinolytic